Pregnancy and Neonatal Outcomes in SARS-CoV-2 Infection: a systematic review

Chamseddine, Reem S.; Wahbeh, Farah; Chervenak, Frank A.; Salomon, Laurent; Ahmed, Badreldeen; Rafii, Arash

doi:10.1101/2020.05.11.20098368

Cited by 10 publications

(21 citation statements)

References 32 publications

(59 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our initial search yielded 1132 references. After the initial screening, we assessed the eligibility of 77 full‐text articles; we excluded 25 of them (see Supplementary material, Table ), which led to the inclusion of 52 SRs 7,9,11,21‐69 . Figure 1 provides the PRISMA flow diagram.…”

Section: Resultsmentioning

confidence: 99%

“…Most of the SRs were published as journal articles, 7,9,11,22,23,25‐27,29‐36,38‐44,46‐49,51,52,54‐58,61‐67 while some were available as pre‐print articles 21,24,28,37,45,50,53,59,60,68,69 . The SRs were published between 17 March 2020 7 and 4 September 2020 33 .…”

Section: Resultsmentioning

confidence: 99%

“…33 SRs 11,22,23,25‐27,30,31,33,35‐37,40‐44,47,48,50‐53,55,58‐62,64,66‐68 assessed the requirement of admission to intensive care or mechanical ventilation support, with overall rates varying from 2.1% to 28.5% and from 1.6% to 11%, respectively. Forty‐two SRs estimated preterm deliveries for <37 weeks of gestation, 7,9,11,21‐33,35‐40,43‐45,48‐53,56,58‐64,66,67,69 with rates varying between 14.3% and 61.2%. Another eight SRs 11,21,33,36,39,44,48,64 estimated preterm deliveries for <34 weeks of gestation, with rates varying between 3.3% and 40.3%.…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Maternal and perinatal outcomes related to COVID‐19 and pregnancy: An overview of systematic reviews

Vergara-Merino

Meza

Couve‐Pérez

et al. 2021

Acta Obstet Gynecol Scand

View full text Add to dashboard Cite

Introduction: Evidence about COVID-19 and pregnancy has rapidly increased since December 2019, making it difficult to make rigorous evidence-based decisions. The objective of this overview of systematic reviews is to conduct a comprehensive analysis of the current evidence on prognosis of COVID-19 in pregnant women. Material and methods: We used Living OVerview of Evidence (L•OVE) platform for COVID-19, which continually retrieves studies from 46 data sources (including Pubmed/MEDLINE, Embase, other electronic databases, clinical trials registries, preprint repositories, among other sources relevant to COVID-19), mapping them into PICO questions. The search covered the period from the inception date of each database to September 13, 2020. We included systematic reviews assessing outcomes of pregnant women with COVID-19 and/or their newborns. Two authors independently screened the titles and abstracts, assessed full-texts to select the studies that met the inclusion criteria, extracted data, and appraised the risk of bias of each included systematic review. We measured the overlap of primary studies included among the selected systematic reviews by building a matrix of evidence, calculating the corrected covered area, and assessing the level of overlapping for every pair of systematic reviews. Results: Our search yielded 1132 references. 52 systematic reviews met inclusion criteria and were included in this overview. Only one review had a low risk of bias, three had an unclear risk of bias, and 48 had a high risk of bias. Most of the included reviews were highly overlapped among each other. In the included reviews, rates of maternal death varied from 0% to 11.1%, admission to intensive care from 2.1% to 28.5%, preterm deliveries before 37 weeks from 14.3% to 61.2%, and cesarean delivery from 48.3% to 100%. Regarding neonatal outcomes, neonatal death varied from 0% to 11.7% while the estimated infection status of the newborn varied between 0% and 11.5%. Conclusions: Only one of 52 systematic reviews had a low risk of bias. Results were heterogenous and the overlap of primary studies was frequently very high between pairs of systematic reviews. High quality evidence syntheses of comparative studies are needed to guide future clinical decisions.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Maternal and perinatal outcomes related to COVID‐19 and pregnancy: An overview of systematic reviews

Vergara-Merino

Meza

Couve‐Pérez

et al. 2021

Acta Obstet Gynecol Scand

View full text Add to dashboard Cite

show abstract

“…Since, several articles have reported that the possibilities of vertical transmission (37,38), highlighting the importance of long-follow up of newborns (39). To clarify the vertical transmission and neonatal outcomes due to SARS-CoV-2 infection; we further compared our findings with other recently published systematic review and meta-analyses (38,(40)(41)(42)(43)(44)(45)(46)(47)(48)(49)(50). Raschetti et al (38) evaluated neonatal outcomes from 74 published articles in where 30% of neonates were reported in the possible vertical transmission and 70% were from environmental sources ( Table 4).…”

Section: Comparison With Recent Findingsmentioning

confidence: 98%

Clinical Characteristics and Neonatal Outcomes of Pregnant Patients With COVID-19: A Systematic Review

et al. 2020

View full text Add to dashboard Cite

Background and Objective: Coronavirus disease 2019 (COVID-19) characterized by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has created serious concerns about its potential adverse effects. There are limited data on clinical, radiological, and neonatal outcomes of pregnant women with COVID-19 pneumonia. This study aimed to assess clinical manifestations and neonatal outcomes of pregnant women with COVID-19.Methods: We conducted a systematic article search of PubMed, EMBASE, Scopus, Google Scholar, and Web of Science for studies that discussed pregnant patients with confirmed COVID-19 between January 1, 2020, and April 20, 2020, with no restriction on language. Articles were independently evaluated by two expert authors. We included all retrospective studies that reported the clinical features and outcomes of pregnant patients with COVID-19.Results: Forty-seven articles were assessed for eligibility; 13 articles met the inclusion criteria for the systematic review. Data is reported for 235 pregnant women with COVID-19. The age range of patients was 25–40 years, and the gestational age ranged from 8 to 40 weeks plus 6 days. Clinical characteristics were fever [138/235 (58.72%)], cough [111/235 (47.23%)], and sore throat [21/235 (8.93%)]. One hundred fifty six out of 235 (66.38%) pregnant women had cesarean section, and 79 (33.62%) had a vaginal delivery. All the patients showed lung abnormalities in CT scan images, and none of the patients died. Neutrophil cell count, C-reactive protein (CRP) concentration, ALT, and AST were increased but lymphocyte count and albumin levels were decreased. Amniotic fluid, neonatal throat swab, and breastmilk samples were taken to test for SARS-CoV-2 but all found negativ results. Recent published evidence showed the possibility of vertical transmission up to 30%, and neonatal death up to 2.5%. Pre-eclampsia, fetal distress, PROM, pre-mature delivery were the major complications of pregnant women with COVID-19.Conclusions: Our study findings show that the clinical, laboratory and radiological characteristics of pregnant women with COVID-19 were similar to those of the general populations. The possibility of vertical transmission cannot be ignored but C-section should not be routinely recommended anymore according to latest evidences and, in any case, decisions should be taken after proper discussion with the family. Future studies are needed to confirm or refute these findings with a larger number of sample sizes and a long-term follow-up period.

show abstract

“…According to two reports of 18 infected mothers in the third trimester, all neonates tested negative for the COVID-19. Still a baby tested positive who was born from a mother suffering from the COVID-19 in London (Chamseddine et al 2020).…”

Section: Clinical Featuresmentioning

confidence: 99%

Taming of Covid-19: potential and emerging application of mesenchymal stem cells

et al. 2021

View full text Add to dashboard Cite

Coronavirus Disease 2019 (COVID-19) caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has turned out to cause a pandemic, with a sky scraping mortality. The virus is thought to cause tissue injury by affecting the reninangiotensin system. Also, the role of the overactivated immune system is noteworthy, leading to severe tissue injury via the cytokine storms. Thus it would be feasible to modulate the immune system response in order to attenuate the disease severity, as well as treating the patients. Today different medicines are being administered to the patients, but regardless of the efficacy of these treatments, adverse effects are pretty probable. Meanwhile, mesenchymal stem cells (MSCs) prove to be an effective candidate for treating the patients suffering from COVID-19 pneumonia, owing to their immunomodulatory and tissue-regenerative potentials. So far, several experiments have been conducted; transplanting MSCs and results are satisfying with no adverse effects being reported. This paper aims to review the recent findings regarding the novel coronavirus and the conducted experiments to treat patients suffering from COVID-19 pneumonia utilizing MSCs.

show abstract

Pregnancy and Neonatal Outcomes in SARS-CoV-2 Infection: a systematic review

Cited by 10 publications

References 32 publications

Maternal and perinatal outcomes related to COVID‐19 and pregnancy: An overview of systematic reviews

Maternal and perinatal outcomes related to COVID‐19 and pregnancy: An overview of systematic reviews

Clinical Characteristics and Neonatal Outcomes of Pregnant Patients With COVID-19: A Systematic Review

Taming of Covid-19: potential and emerging application of mesenchymal stem cells

Contact Info

Product

Resources

About